Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Investigating the role of GNA13 Mutations in non-Hodgkin Lymphoma

FY 2011-12

Summary
In 2011, Canada Cancer statistics estimated 7,200 people would be diagnosed with non-Hodgkin lymphoma (NHL) and 3,000 patients would die from NHL. Lymphomas are cancers of the immune system that develop in lymph nodes. Lymphoid cancers develop when normal white blood cells acquire spontaneous or chemically (carcinogen) induced changes in their cell division and growth instructions. A cell uses DNA to store all of its instructions, and specific instructions are stored (encoded) in discrete units called genes. The instructions encoded in genes describe how to make a certain protein, which will then go on to perform a specific task in the cell. Cancer is caused when certain proteins that control growth are inactivated or not produced because of alterations (mutations) made to the genes that describe how the proteins are made. Recently our lab determined the entire sequence of DNA from 13 cases of a subtype of NHL termed diffuse large B-cell lymphoma (DLBCL). Analysis of the DNA revealed mutations in 109 genes. One of these genes frequently altered is called GNA13, and mutations in this gene are correlated with decreased patient survival. GNA13 encodes a protein called Galpha13, which plays a role in the ability of a cell to migrate to a different location. This is an important hallmark of aggressive cancers because it allows the cancer to spread to different areas in the body. Therefore, I will first study the types of GNA13 mutations in DLBCL to determine if they inactivate or hyper-activate the function Galpha13. Secondly I will examine how well cells with mutated GNA13 are able to move. Current treatments are only able to cure 50% of DLBCL cases, indicating the development of new DLBCL treatments is required. Therefore, determining how mutations in GNA13 are promoting more aggressive forms of DLBCL is important because Galpha13 could be a target to develop new drugs against in order to treat DLBCL.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
255328
Name
Huff Ryan D
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Investigating the role of GNA13 Mutations in non-Hodgkin Lymphoma
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Cell Invasion; Cancer Cell Migration; Immunohistochemistry; Mutations; Non-Hodgkin'S Lymphoma; Signal Transduction; Western Blot; Wound Healing Assay
Abstract
In 2011, Canada Cancer statistics estimated 7,200 people would be diagnosed with non-Hodgkin lymphoma (NHL) and 3,000 patients would die from NHL. Lymphomas are cancers of the immune system that develop in lymph nodes. Lymphoid cancers develop when normal white blood cells acquire spontaneous or chemically (carcinogen) induced changes in their cell division and growth instructions. A cell uses DNA to store all of its instructions, and specific instructions are stored (encoded) in discrete units called genes. The instructions encoded in genes describe how to make a certain protein, which will then go on to perform a specific task in the cell. Cancer is caused when certain proteins that control growth are inactivated or not produced because of alterations (mutations) made to the genes that describe how the proteins are made. Recently our lab determined the entire sequence of DNA from 13 cases of a subtype of NHL termed diffuse large B-cell lymphoma (DLBCL). Analysis of the DNA revealed mutations in 109 genes. One of these genes frequently altered is called GNA13, and mutations in this gene are correlated with decreased patient survival. GNA13 encodes a protein called Galpha13, which plays a role in the ability of a cell to migrate to a different location. This is an important hallmark of aggressive cancers because it allows the cancer to spread to different areas in the body. Therefore, I will first study the types of GNA13 mutations in DLBCL to determine if they inactivate or hyper-activate the function Galpha13. Secondly I will examine how well cells with mutated GNA13 are able to move. Current treatments are only able to cure 50% of DLBCL cases, indicating the development of new DLBCL treatments is required. Therefore, determining how mutations in GNA13 are promoting more aggressive forms of DLBCL is important because Galpha13 could be a target to develop new drugs against in order to treat DLBCL.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Huff, Ryan D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~